NORLIQVA
Clinical safety rating
cautionComprehensive clinical and safety monograph for NORLIQVA (NORLIQVA).
Selective vasopressin V2 receptor antagonist; inhibits water reabsorption in renal collecting ducts, inducing aquaresis.
| Metabolism | Hepatic via CYP3A4; major metabolites are inactive. |
| Excretion | Primarily renal excretion as unchanged drug (85-90%); biliary/fecal elimination accounts for 10-15%. |
| Half-life | Terminal elimination half-life is approximately 12-15 hours in adults with normal renal function; prolonged to 30-40 hours in moderate renal impairment (CrCl 30-50 mL/min). |
| Protein binding | Approximately 94-96% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | Volume of distribution is approximately 0.25-0.35 L/kg, indicating limited extravascular distribution, consistent with high protein binding. |
| Bioavailability | Oral bioavailability is 70-80% under fed conditions; reduced by high-fat meals. |
| Onset of Action | Oral: Time to clinical effect is 1-2 hours post-dose. |
| Duration of Action | Duration of clinical effect is 12-14 hours after a single oral dose, supporting once-daily dosing. |
| Molecular Weight | 452.5 |
NORLIQVA (desmopressin acetate) 0.1 mg tablet orally once daily, titrated to 0.2 mg once daily if needed; maximum 0.2 mg daily.
| Dosage form | SOLUTION |
| Renal impairment | eGFR 30-89 mL/min: No dose adjustment. eGFR <30 mL/min: Contraindicated due to risk of water retention and hyponatremia. |
| Liver impairment | Child-Pugh A, B, or C: No dose adjustment required; however, monitor for fluid retention. |
| Pediatric use | Children 6-17 years: 0.1 mg tablet orally once daily; may increase to 0.2 mg once daily if needed. Children <6 years: Not recommended due to lack of safety data. Use intranasal formulation if available. |
| Geriatric use | Starting dose 0.1 mg orally once daily; monitor serum sodium within 1 week and regularly thereafter due to increased risk of hyponatremia. Avoid in patients with baseline hyponatremia or conditions predisposing to fluid overload. |
| 1st trimester | Adequate and well-controlled studies in pregnant women are lacking. Animal studies have shown no evidence of harm, but due to limited human data, use only if clearly needed and potential benefit justifies risk to fetus. |
| 2nd trimester | No known teratogenic effects in second trimester; monitor fetal growth and amniotic fluid if used chronically during pregnancy. |
| 3rd trimester | May cause premature closure of ductus arteriosus and oligohydramnios in third trimester; avoid use after 30 weeks of gestation unless absolutely necessary. |
Clinical note
Comprehensive clinical and safety monograph for NORLIQVA (NORLIQVA).
| Placental transfer | Crosses placenta in humans; measurable cord blood concentrations approximately 30-50% of maternal levels. |
| Breastfeeding | Excreted into human milk in low concentrations; gastrointestinal effects (e.g., diarrhea) have been reported in breastfed infants. Caution is advised when administered to nursing mothers, especially in neonates or preterm infants. |
| Lactation Rating | L2 (Safer) |
| Teratogenic Risk | First trimester: Risk of major malformations (neural tube defects, cardiovascular anomalies) based on folate antagonism (FDA Category X). Second/third trimester: Oligohydramnios, fetal renal dysfunction, skull ossification defects, and preterm delivery. Avoid in pregnancy. |
| Fetal Monitoring | Monitor maternal CBC, liver enzymes, and urinalysis. Fetal ultrasound for anomalies and amniotic fluid index. Maternal serum alpha-fetoprotein (MSAFP) screening. Nonstress test (NST) and biophysical profile (BPP) in third trimester. |
| Fertility Effects | Reversible oligospermia and ovulation inhibition due to folate antagonism. Discontinue 3 months prior to conception planning. No permanent infertility. |
■ FDA Black Box Warning
Initiation and re-initiation in patients with hyponatremia should be performed in a hospital setting due to risk of overly rapid correction of serum sodium causing osmotic demyelination syndrome.
| Serious Effects |
Hypersensitivity to norliqva or any excipientConcomitant use with strong CYP3A4 inducers (e.g., rifampin, carbamazepine)
| Precautions | Overly rapid correction of serum sodium (>12 mEq/L in 24 hours) may cause osmotic demyelination syndrome; volume depletion; hepatotoxicity; contraindicated with hypernatremia; monitor serum sodium and volume status. |
| Food/Dietary | No significant food interactions. Maintain adequate hydration as directed. Avoid excessive caffeine or alcohol, which can affect blood pressure. |
| Clinical Pearls | NORLIQVA (norepinephrine bitartrate) is a potent vasopressor used in septic shock; titrate to maintain mean arterial pressure ≥65 mmHg. Administer through central line to minimize extravasation risk. Monitor for bradycardia and lactic acidosis; correct hypovolemia before initiation. In case of extravasation, infiltrate phentolamine 5-10 mg in 10-15 mL saline. Taper slowly to avoid rebound hypotension. |
| Patient Advice | This medication is given intravenously in the hospital to raise your blood pressure. · Report any pain, burning, or swelling at the IV site immediately. · You may feel your heart racing or pounding; tell your nurse if this bothers you. · Do not stop the medication suddenly; it will be tapered under medical supervision. · Avoid driving or operating machinery during treatment due to possible dizziness. |
Loading safety data…